Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Granisetron Transdermal Patch for Prophylaxis of Nausea and Vomiting in Patients Receiving Oral Anticancer Agents

Phase 2

Conditions: Chemotherapy-induced Nausea and Vomiting (CINV)

Interventions: Drug: Granisetron Transdermal Delivery System

First Posted Date: 2020-07-15

Last Posted Date: 2022-04-20

Lead Sponsor: Fudan University

Target Recruit Count: 60

Registration Number: NCT04472143

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Clinical Study of Imaging Genomics Based on Machine Learning for BCIG

Conditions: Image, Body
Breast Cancer
Molecular Typing
Pathology

Interventions: Procedure: Multidisciplinary cooperative comprehensive treatment

First Posted Date: 2020-07-08

Last Posted Date: 2020-08-21

Lead Sponsor: Fudan University

Target Recruit Count: 1500

Registration Number: NCT04461990

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Compression Gloves to Reduce Albumin-binding Paclitaxel Induced Peripheral Sensory and Motor Neurotoxicity (REMAINING)

Not Applicable

Conditions: Peripheral Neuropathy

Interventions: Device: Compression gloves

First Posted Date: 2020-06-25

Last Posted Date: 2020-07-28

Lead Sponsor: Fudan University

Target Recruit Count: 70

Registration Number: NCT04446819

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer

Phase 2

Not yet recruiting

Conditions: Rectal Cancer

Interventions: Drug: Capecitabine (Xeloda) Pharmacogenetic Test Reagents
Drug: irinotecan
Radiation: IMRT
Drug: Oxaliplatin
Drug: Tislelizumab
Drug: 5Fluorouracil

First Posted Date: 2020-06-23

Last Posted Date: 2020-06-30

Lead Sponsor: Fudan University

Target Recruit Count: 222

Registration Number: NCT04443543

Locations: 🇨🇳
Fudan University Shanghai Cancer Cencer, Shanghai, Shanghai, China

Prediction of Immunotherapeutic Effect of Advanced Non-small Cell Lung Cancer

Not Applicable

Conditions: NSCLC Patients

Interventions: Drug: nafulizumab
Drug: pabolizumab

First Posted Date: 2020-06-11

Last Posted Date: 2020-06-11

Lead Sponsor: Fudan University

Target Recruit Count: 200

Registration Number: NCT04427475

Locations: 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China

Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC

Phase 2

Conditions: PFS

Interventions: Drug: Gefitinib
Drug: Bevacizumab Combined With Gefitinib

First Posted Date: 2020-06-11

Last Posted Date: 2020-06-12

Lead Sponsor: Fudan University

Target Recruit Count: 120

Registration Number: NCT04425187

Locations: 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China

Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients

Phase 2

Active, not recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Drug: epirubicin hydrochloride
Drug: Cyclophosphamide
Drug: Albumin bound paclitaxel
Drug: Toripalimab

First Posted Date: 2020-06-05

Last Posted Date: 2024-05-21

Lead Sponsor: Fudan University

Target Recruit Count: 70

Registration Number: NCT04418154

Locations: 🇨🇳
Shanghai Cancer Center, Fudan University, Shanghai, Shanghai, China

A Trial Evaluating the Efficacy of Metastasectomy in Patients With Oligo-Metastatic Breast Cancer(OMIT)

Not Applicable

Recruiting

Conditions: Breast Cancer

Interventions: Procedure: Metastasectomy for the metastatic sites

First Posted Date: 2020-06-04

Last Posted Date: 2020-06-04

Lead Sponsor: Fudan University

Target Recruit Count: 172

Registration Number: NCT04413409

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

The Value of Palliative Primary Tumor Resection in Metastatic Colon Cancer

Phase 3

Recruiting

Conditions: Surgery
Metastatic Colon Cancer

Interventions: Procedure: resection of primary tumor
Drug: XELOX
Drug: mFOLFOX6

First Posted Date: 2020-06-04

Last Posted Date: 2020-06-04

Lead Sponsor: Fudan University

Target Recruit Count: 627

Registration Number: NCT04416854

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer

Phase 2

Conditions: Locally Advanced Rectal Cancer

Interventions: Drug: PD-1 antibody
Drug: Capecitabine
Drug: Irinotecan
Radiation: Neoadjuvant Radiotherapy

First Posted Date: 2020-06-02

Last Posted Date: 2020-06-02

Lead Sponsor: Fudan University

Target Recruit Count: 50

Registration Number: NCT04411524

Locations: 🇨🇳
Zhen Zhang, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy